Literature DB >> 3370062

Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.

M Lesne1.   

Abstract

The pharmacodynamic effects and the pharmacokinetic parameters of torasemide (1-isopropyl-3- ([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) 20 mg and furosemide 40 mg were compared after oral and intravenous administration in 6 healthy volunteers. The plasma elimination half-life for i.v. and oral torasemide was 2.2 h and 2.8 h, its bioavailability after oral administration was 91%, about 25% of the total body clearance was due to renal excretion both after iv. or oral application. For furosemide, a plasma elimination half-life of 0.6 h for i.v. and 0.8 h for oral application was found. The bioavailability was 40%, and about 62% of the drug was excreted via the kidney. Both drugs produced a similar diuretic and natriuretic effect. However, torasemide showed an increased duration of action compared to furosemide and a higher relation between urinary Na and K excretion, both after i.v. and oral administration, suggesting less loss of potassium after To. Both agents were well tolerated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370062

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  15 in total

Review 1.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and pharmacodynamics of torasemide.

Authors:  H Knauf; E Mutschler
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 3.  Acute and long term effects of loop diuretics in heart failure.

Authors:  F Krück
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Clinical pharmacology of loop diuretics.

Authors:  D C Brater
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide.

Authors:  T Risler; B Krämer; G A Müller
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 6.  Torasemide. An update of its pharmacological properties and therapeutic efficacy.

Authors:  C J Dunn; A Fitton; R N Brogden
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

7.  Torasemide in the treatment of patients with cirrhosis and ascites.

Authors:  P Gentilini; G Laffi; G La Villa; V Carloni; M Foschi; R G Romanelli; F Marra
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

8.  Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency--preliminary evaluation.

Authors:  D C Brater; D R Rudy; J R Voelker; P K Greene; T Gehr; D A Sica
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 9.  Torasemide in advanced renal failure.

Authors:  J Kindler
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

10.  Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study.

Authors:  F Fiaccadori; G Pedretti; G Pasetti; P Pizzaferri; G Elia
Journal:  Clin Investig       Date:  1993-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.